Bristol Myers Squibb's arlo-cel meets Phase 2 endpoints in quadruple-class exposed multiple myeloma
核心洞察
Bristol Myers Squibb (搜索)'s GPRC5D (搜索)-directed CAR T therapy arlocabtagene autoleucel met its primary overall response rate endpoint in the registrational Phase 2 QUINTESSENTIAL trial.
The trial enrolled adults with quadruple-class exposed relapsed and refractory multiple myeloma (搜索) who had received four or more prior lines of therapy.
Key secondary endpoints of complete response rate were also met in patients with three or more prior lines of therapy, with safety consistent with existing CAR T therapies.
Bristol Myers Squibb (搜索) reported positive Phase 2 results for arlocabtagene autoleucel (arlo-cel), an experimental autologous CAR T cell therapy, in patients with quadruple-class exposed relapsed and refractory multiple myeloma (搜索) (RRMM). The registrational QUINTESSENTIAL trial (NCT06297226) met its primary endpoint of overall response rate and its key secondary endpoint of complete response rate in this heavily pretreated population.
Arlo-cel is a potential first-in-class autologous G protein-coupled receptor class C group 5 member D (GPRC5D (搜索))-directed CAR T cell therapy designed for single-infusion administration.
Trial Population and Design
QUINTESSENTIAL enrolled adults with quadruple-class exposed RRMM who had received four or more prior lines of therapy. Quadruple-class exposure is defined as prior treatment with an immunomodulatory inhibitor, a proteasome inhibitor, an anti-CD38 (搜索) therapy, and a BCMA (搜索)-targeted therapy.
The study demonstrated a statistically significant and clinically meaningful overall response rate in this cohort. The trial also met the key secondary endpoints of overall response rate and complete response rate in patients with RRMM who were quadruple-class exposed after three or more prior lines of therapy.
Treatment Process and Safety
Arlo-cel is administered as a single infusion. The complete treatment process requires collecting T cells from the patient's bloodstream, administering bridging therapy, manufacturing the specific CAR T cells, and applying lymphodepleting chemotherapy before the final infusion and safety monitoring period.
Trial investigators reported that the safety profile of arlo-cel remains consistent with other existing CAR T cell therapies and GPRC5D (搜索)-targeting options used to treat multiple myeloma.
Next Steps
Bristol Myers Squibb (搜索) intends to share comprehensive results from the QUINTESSENTIAL study during an upcoming medical meeting.
Separate Myeloma Filing Advances
In a distinct multiple myeloma program, Bristol Myers Squibb (搜索) announced that the U.S. Food and Drug Administration has accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) for patients with RRMM. The FDA granted a Prescription Drug User Fee Act date of May 13, 2027, for the indication.
The filing is supported by results from the Phase 3 SUCCESSOR-2 trial, an inferential, seamless Phase 3, multicenter, randomized, open-label study that evaluated MeziKd against carfilzomib and dexamethasone (Kd). The primary endpoint was progression-free survival.
MeziKd reduced the risk of disease progression or death by 52% compared with Kd, with a median progression-free survival of 18.0 months versus 8.3 months (HR: 0.48; p<0.0001). The safety profile was consistent with prior studies of mezigdomide and the known profiles of the individual agents.
The analysis included 479 patients, 288 receiving MeziKd and 191 receiving Kd. Median patient age was 68, with 25.1% aged 75 or older, and patients had received a median of two prior therapies. The population was heavily pretreated: 92.1% were triple-class exposed, 85.8% were refractory to an anti-CD38 (搜索) monoclonal antibody, and 75.8% were refractory to lenalidomide.
Mezigdomide is an oral cereblon E3 ligase modulator (CELMoD) optimized to degrade the Ikaros (搜索) and Aiolos (搜索) target proteins. It is also being evaluated in the ongoing Phase 3 SUCCESSOR-1 trial. Results from SUCCESSOR-2 were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The Lancet.
Cristian Massacesi, MD, executive vice president, chief medical officer and head of development at Bristol Myers Squibb (搜索), said the company now has two distinct agents under review for this indication and remains committed to leveraging its CELMoD platform to advance treatments for hematologic malignancies and solid tumors.